FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD

Disclosures

January 11, 2018

In This Article

Prevymis (letermovir)

Indication:

Cytomegalovirus (CMV) prophylaxis in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

Mechanism:

Antiviral agent against CMV. It inhibits the CMV DNA terminase complex (pUL51, pUL56, and pUL89), which is required for viral DNA processing, thereby interfering with virion maturation.

Dosage:

480 mg PO/IV once daily. Initiate between day 0 and day 28 posttransplantation (before or after engraftment) and continue through day 100.

Approval:

Approval was based on a phase 3 clinical trial (n=565). In this study, significantly fewer patients developed clinically significant CMV infection in the letermovir group (38%, n=122/325) compared to the placebo group (61%, n=103/170). Additionally, fewer patients discontinued treatment or had missing data through week 24 post-HSCT (P<0.0001).

Reference:

Marty FM, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 Dec 21;377(25):2433-2444.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....